ACALABRUTINIB

Acalabrutinib is a selective Bruton's tyrosine kinase (BTK) inhibitor used primarily in the treatment of certain types of blood cancers. It works by interfering with the growth and spread of cancer cells.

Indications

-Chronic lymphocytic leukemia (CLL) -Small lymphocytic lymphoma (SLL) -Mantle cell lymphoma (MCL) -Other B-cell malignancies as determined by a healthcare provider

Dosage

The typical dose of Acalabrutinib for CLL/SLL is 100 mg taken orally twice daily. For MCL, the usual dosage is 200 mg taken orally twice daily. Dosage adjustments may be necessary based on individual patient needs and response to treatment.

Contra-Indications

-Hypersensitivity to Acalabrutinib or any component of the formulation -Severe hepatic impairment -Co-administration with strong CYP3A inhibitors

Special Precautions

-Monitor for signs of bleeding or bruising, especially in patients with a history of bleeding disorders -Regular monitoring of blood counts is recommended -Use with caution in patients with a history of cardiovascular events -Avoid live vaccines during treatment

Side Effects

Common side effects include: -Headache -Diarrhea -Fatigue -Nausea -Bruising or bleeding -Rash Serious side effects may include: -Infections -Heart problems (e.g., atrial fibrillation) -Liver enzyme abnormalities

Drug Interactions

-Avoid use with strong CYP3A inhibitors (e.g., ketoconazole, ritonavir) -Caution with other medications that increase bleeding risk (e.g., anticoagulants, antiplatelet agents) -Inform your healthcare provider about all medications and supplements you are taking